Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Robert Redd"'
Autor:
David J Lee, Elizabeth K O'Donnell, Noopur Raje, Cristina Panaroni, Robert Redd, Jennifer Ligibel, Dorothy D Sears, Omar Nadeem, Irene M Ghobrial, Catherine R Marinac
Publikováno v:
JMIR Research Protocols, Vol 13, p e51368 (2024)
BackgroundObesity is an established, modifiable risk factor of multiple myeloma (MM); yet, no lifestyle interventions are routinely recommended for patients with overweight or obesity with MM precursor conditions. Prolonged nightly fasting is a simpl
Externí odkaz:
https://doaj.org/article/2337909fc38a47099368b1c9f66691d9
Autor:
Jennifer L. Crombie, Caron A. Jacobson, Robert Redd, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Jordan Gauthier, Erin Mullane, Kirk Cahill, Justin Kline, Jason Romancik, Jonathon B. Cohen, Anna Saucier, Roch Houot, Philippe Armand, Brian Hess
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/5acdfcb9d33441d58498adc67547a25c
Autor:
Mark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, Robert Redd, Eileen M. Boyle, Benny Zhitomirsky, Andrew J. Dunford, Yu-Tzu Tai, Selina J. Chavda, Cody Boehner, Carl Jannes Neuse, Mahshid Rahmat, Ankit Dutta, Tineke Casneuf, Raluca Verona, Efstathis Kastritis, Lorenzo Trippa, Chip Stewart, Brian A. Walker, Faith E. Davies, Meletios-Athanasios Dimopoulos, P. Leif Bergsagel, Kwee Yong, Gareth J. Morgan, François Aguet, Gad Getz, Irene M. Ghobrial
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Existing clinical models cannot fully capture smoldering multiple myeloma (SMM) heterogeneity. Here, integration of 42 genetic alterations from 214 SMM patients using an unsupervised binary matrix factorization clustering approach results in the iden
Externí odkaz:
https://doaj.org/article/078805a3b909435fb477a229095a08ed
Autor:
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schöder, Heather Jacene
Publikováno v:
HemaSphere, Vol 7, Iss 2, p e826 (2023)
While most patients with follicular lymphoma (FL) have excellent outcomes with frontline chemoimmunotherapy (CIT), a subset of patients will experience early progression, which is associated with poor subsequent outcomes. Novel biomarkers are needed
Externí odkaz:
https://doaj.org/article/83d25c36f6aa4d008cd0ecfabeefe63a
Autor:
Adeel M Khan, Thita Chiasakul, Robert Redd, Rushad Patell, Ellen P McCarthy, Donna Neuberg, Jeffrey I Zwicker
Publikováno v:
PLoS Medicine, Vol 19, Iss 5, p e1004012 (2022)
BackgroundDirect oral anticoagulants (DOACs) have comparable efficacy with low-molecular-weight heparin (LMWH) for the treatment of cancer-associated venous thromboembolism (VTE). Whether there is a mortality benefit of DOACs compared with warfarin i
Externí odkaz:
https://doaj.org/article/0a0d848ac2a44ee3b79a361c58f5ffee
Autor:
Elisa ten Hacken, Kendell Clement, Shuqiang Li, María Hernández-Sánchez, Robert Redd, Shu Wang, David Ruff, Michaela Gruber, Kaitlyn Baranowski, Jose Jacob, James Flynn, Keith W. Jones, Donna Neuberg, Kenneth J. Livak, Luca Pinello, Catherine J. Wu
Publikováno v:
Genome Biology, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract CRISPR-Cas9 gene editing has transformed our ability to rapidly interrogate the functional impact of somatic mutations in human cancers. Droplet-based technology enables the analysis of Cas9-introduced gene edits in thousands of single cells
Externí odkaz:
https://doaj.org/article/0fc6668360f84aa68cc28a219254ce26
Autor:
Tarek H. Mouhieddine, Adam S. Sperling, Robert Redd, Jihye Park, Matthew Leventhal, Christopher J. Gibson, Salomon Manier, Amin H. Nassar, Marzia Capelletti, Daisy Huynh, Mark Bustoros, Romanos Sklavenitis-Pistofidis, Sabrin Tahri, Kalvis Hornburg, Henry Dumke, Muhieddine M. Itani, Cody J. Boehner, Chia-Jen Liu, Saud H. AlDubayan, Brendan Reardon, Eliezer M. Van Allen, Jonathan J. Keats, Chip Stewart, Shaadi Mehr, Daniel Auclair, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, David P. Steensma, Jacob P. Laubach, Paul G. Richardson, Jerome Ritz, Benjamin L. Ebert, Robert J. Soiffer, Lorenzo Trippa, Gad Getz, Donna S. Neuberg, Irene M. Ghobrial
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Multiple myeloma (MM) is treated with induction chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. Here, the authors show that the presence of clonal haematopoiesis of indeterminate potential
Externí odkaz:
https://doaj.org/article/26a4f18ed00849e6bce820eacad6b32d
Autor:
Wendy B.C. Stevens, Matias Mendeville, Robert Redd, Andrew J. Clear, Reno Bladergroen, Maria Calaminici, Andreas Rosenwald, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Luc Xerri, Gilles Salles, Wolfram Klapper, Michael Pfreundschuh, Andrew Jack, Randy D. Gascoyne, Yasodha Natkunam, Ranjana Advani, Eva Kimby, Birgitta Sander, Laurie H. Sehn, Anton Hagenbeek, John Raemaekers, John Gribben, Marie José Kersten, Bauke Ylstra, Edie Weller, Daphne de Jong
Publikováno v:
Haematologica, Vol 102, Iss 8 (2017)
In follicular lymphoma, studies addressing the prognostic value of microenvironment-related immunohistochemical markers and tumor cell-related genetic markers have yielded conflicting results, precluding implementation in practice. Therefore, the Lun
Externí odkaz:
https://doaj.org/article/b6733729e0b74565b0f6b902d4cf130a
Autor:
Rifaquat Rahman, Steffen Ventz, Robert Redd, Timothy Cloughesy, Brian M. Alexander, Patrick Y. Wen, Lorenzo Trippa
Publikováno v:
Clinical Cancer Research. :OF1-OF5
Drug development can be associated with slow timelines, particularly for rare or difficult-to-treat solid tumors such as glioblastoma. The use of external data in the design and analysis of trials has attracted significant interest because it has the
Autor:
Jeremy S. Abramson, Elizabeth Bengston, Robert Redd, Jeffrey A. Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal Shah, Eric Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann S. LaCasce, Celeste M. Bello
Publikováno v:
Blood Advances. 7:1130-1136
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is ap